APC (APC regulator of Wnt signaling pathway; HGNC:583, NCBI Gene 324) is the gene on chromosome 5q22.2 encoding the large scaffold protein that, with axin and GSK3β, forms the destruction complex degrading β-catenin — keeping Wnt growth signaling off unless a ligand arrives. Its loss-of-function is the initiating event of most colorectal cancer (the chromosomal-instability pathway's first hit, per the Vogelstein model), and germline mutations cause familial adenomatous polyposis.
Approved Symbol
APC (HGNC:583)
Chromosomal Locus
5q22.2
Encoded Product
APC — a 312-kDa scaffold (2,843 aa) with 15- and 20-amino-acid β-catenin-binding repeats
Primary Pathway
APC-axin-GSK3β destruction complex → β-catenin degradation → Wnt off
Clinical / Therapeutic Role
Initiating tumor suppressor of colorectal cancer; familial adenomatous polyposis
Gene Structure & Expression
Genomic organization: 21 exons; exon 15 carries the mutation-cluster region — the frame-shifts and nonsense stops of both sporadic and familial colorectal cancer concentrate in its β-catenin-binding repeats, truncating the protein before the axin-binding and microtubule-interaction domains.
Expression: Broad epithelial expression; the protein localizes to the apical tips of crypt cells (the stem-cell zone where Wnt tone sets proliferation — exactly where the first hit lands), plus roles at kinetochores and microtubule plus-ends in dividing cells.
Molecular Function & Pathways
Wnt gatekeeping: The APC-axin complex phosphorylates β-catenin (via GSK3β/CK1), marking it for ubiquitination and proteasomal destruction. Without APC, β-catenin accumulates, enters the nucleus, and partners TCF to switch on MYC and cyclin D1 — Wnt signaling on, permanently.
Chromosomal stability: Beyond Wnt, APC's microtubule and kinetochore attachments guard mitotic fidelity — its loss explaining the chromosomal instability that follows the first hit; the "just-right" hypothesis — mutations leaving minimal β-catenin regulation but some function — fits the selection window of the cluster region.
Clinical & Therapeutic Significance
Cancer genetics: Somatic APC loss in ~80% of sporadic colorectal cancers; germline mutations cause autosomal-dominant familial adenomatous polyposis (hundreds-to-thousands of polyps, colon cancer by mid-life without colectomy; attenuated variants with fewer polyps).
Therapeutics and prevention: Colonoscopic surveillance and prophylactic surgery in FAP; NSAID chemoprevention (celecoxib's historical use); Wnt-pathway drug development (Tankyrase and PORCN inhibitors) still chasing the downstream dependency APC-mutant tumors acquire.